Efficacy of guselkumab compared with adalimumab for psoriasis: a meta-analysis of randomized controlled studies

Introduction: The efficacy of guselkumab versus adalimumab for psoriasis remains controversial. Aim: We conducted a systematic review and meta-analysis to explore the influence of guselkumab versus adalim-umab on treatment efficacy for psoriasis. Material and methods: We have searched PubMed, Embase, Web of Science, EBSCO, and Cochrane library data-bases for randomized controlled trials (RCTs) published until March 2021 and assessing the efficacy and safety of guselkumab versus adalimumab for psoriasis. This meta-analysis was performed using the random-effects model. Results: Three RCTs were included in the meta-analysis. Overall, compared with adalimumab for psoriasis, gusel-kumab was associated with improved PASI 100 (OR = 2.18; 95% CI: 1.47 to 3.23; p = 0.0001), PASI 90 (OR = 2.63; 95% CI: 2.11 to 3.27; p < 0.00001), PASI 75 (OR = 3.10; 95% CI: 2.35 to 4.08; p < 0.00001) and PGA 0/1 (OR = 2.04; 95% CI: 1.26 to 3.31; p = 0.004), as well as decreased DLQI (SMD = -0.24; 95% CI: -0.34 to -0.13; p < 0.00001). In addition, gusel-kumab resulted in higher DLQI score 0/1 (OR = 1.88; 95% CI: 1.51 to 2.33; p < 0.00001) than adalimumab. Conclusions: Guselkumab showed better efficacy than adalimumab for psoriasis.